M&A - ACORN BIOVENTURES, L.P.

Form Type: SCHEDULE 13D

Filing Date: 2025-05-22

Corporate Action: Merger

Type: Update

Accession Number: 000163658725000027

Filing Summary: Acorn Bioventures, L.P. and its associated entities, including Acorn Capital Advisors GP, LLC and others, have reported their acquisition of shares in OnKure Therapeutics, Inc. following a merger that took place on October 4, 2024. The merger involved Radiate Merger Sub I, Inc. and Legacy OnKure, leading to OnKure changing its name from Reneo Pharmaceuticals, Inc. In this merger, Acorn received 1,439,674 shares of the common stock of OnKure. Recently, on May 15, 2025, Acorn and its affiliate Acorn 2 acquired an aggregate of 1,400,000 shares (270,270 and 1,129,730 shares, respectively) of OnKure's common stock at a price of $8.15 per share, totaling approximately $11.41 million. The entities involved intend to continue monitoring their investments and may explore various actions concerning their holdings, though they indicated no immediate changes to governance or structure of OnKure.